Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma

Yang, Zheng; Ni, Weidong; Cui, Chunzhi; Fang, Lijing; Xuan, Yanhua

doi:10.1016/j.yexmp.2017.02.012

Cited by 36 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found evidence that compared with CD146 + CAFs, CD146 -CAFs may encourage tumor growth, as the average volume of excised tumors was significantly different (MCF-7CD146 -CAF, 570 ± 313 mm 3 versus MCF-7/CD146 + CAF, 195 ± 99 mm 3 ; P = 0.0171; Figure 5F). Surprisingly, when we graphed CD146 + CAF-bearing tumors alone (blue dots), CD146 -CAF-bearing tumors alone (red dots), or both combined, there was no correlation between final tumor volume and the number of total lesions per lung ( Figure 5G).…”

Section: Resultsmentioning

confidence: 63%

“…Dysregulation of both structural (i.e., collagen I and IV, proteoglycans, and glycoproteins) and matricellular components of the TME (i.e., growth factors, metalloproteinases, tissue inhibitors of metalloproteinases, chemokines, and cytokines) has been linked with development of metastases in multiple cancer types (1,2). For example, in breast tissue, the glycoprotein tenascin C (TNC) is often overexpressed at the invasive front of aggressive and metastatic breast tumors (3,4). TNC uses its fibronectin 1 (FN1) and EGF-like repeat domains to change cancer cell adhesion, proliferation, and migration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fibroblast subtypes define a metastatic matrisome in breast cancer

Brechbuhl¹,

Barrett²,

Kopin³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 63%

Section: Introductionmentioning

confidence: 99%

Fibroblast subtypes define a metastatic matrisome in breast cancer

Brechbuhl¹,

Barrett²,

Kopin³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…S1 . We ultimately identified 15 studies containing 3680 breast cancer patients for the assessment of activated fibroblasts 8 - 17 , 23 - 27 , and then evaluated all these studies with the Newcastle-Ottawa Scale (NOS). Characteristics of included studies being in accordance with the inclusion criteria and suitable for data consolidation were shown in Table 1 and Table S1 .…”

Section: Resultsmentioning

confidence: 99%

Activated Tumor-infiltrating Fibroblasts Predict Worse Prognosis in Breast Cancer Patients

Zhong

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Purpose: Activated tumor-infiltrating fibroblasts were significantly associated with survival of cancer patients. However, they are heterogeneous population, and the prognostic role of these cells in human breast cancer still remains controversial. Herein, we performed the meta-analysis to better understand the role of these cells in prognosis prediction for breast cancer patients.Methods: We searched PubMed and EBSCO to identify the studies evaluating the association of intratumoral activated fibroblast density detected by immunohistochemical (IHC) method and overall survival (OS) and/or disease-free survival (DFS) in breast cancer patients, then computed extracted data into hazard ratios (HRs) for OS, DFS and clinicopathological features such as lymph node metastasis, TNM stage with STATA 12.0.Results: A total of 3680 patients with breast cancer from 15 published studies were incorporated into this meta-analysis. We found that the infiltration of activated fibroblasts significantly decreased overall survival (OS) and disease-free survival (DFS) in patients. In stratified analyses, high density of FSP-1+ or podoplanin+ fibroblasts was significantly associated with worse OS; while α-SMA+ or podoplanin+ fibroblast infiltration was associated with worse DFS in breast cancer. In addition, elevated number of activated tumor-infiltrating fibroblasts significantly correlated with lymph node metastasis and poor tumor differentiation of patients.Conclusion: The infiltration of activated fibroblasts, especially the FSP-1+ or podoplanin+ fibroblasts leads to worse clinical outcome in breast cancer patients, implicating that it is a valuable prognostic biomarker and targeting it may have a potential for effective treatment.

show abstract

“…This data suggests that the CAF may produce soluble factors in the medium to promote NSCLC cell survival under stress of chemotherapy drugs. To further determine the key factors in the CAF‐secreted cytokines involved in NSCLC drug resistance, we screened the expression of IGF2 , SDF‐1 , HGF , VEGF α, FGF , EGF , PDGF , CTGF , Tenascin , TSP‐1 and Fibronectin in the CAF pre‐co‐cultured with or without LCP1 cells and found that IGF2 , VEGFa and EGF were significantly upregulated, especially the IGF2 (Figure C). Moreover, we used the recombinant IGF2 to pre‐treat LCP1 and A549 cells, followed by cisplatin, etoposide and vinorelbine diatrate treatment.…”

Section: Resultsmentioning

confidence: 99%

Reverse of non‐small cell lung cancer drug resistance induced by cancer‐associated fibroblasts via a paracrine pathway

et al. 2018

View full text Add to dashboard Cite

The tumor microenvironment orchestrates the sustained growth, metastasis and recurrence of cancer. As an indispensable component of the tumor microenvironment, cancer‐associated fibroblasts (CAF) are considered as an essential synthetic machine producing various tumor components, leading to cancer sustained stemness, drug resistance and tumor recurrence. Here, we developed a sustainable primary culture of lung cancer cells fed with lung cancer‐associated fibroblasts, resulting in enrichment and acquisition of drug resistance in cancer cells. Moreover, IGF2/AKT/Sox2/ABCB1 signaling activation in cancer cells was observed in the presence of CAF, which induces upregulation of P‐glycoprotein expression and the drug resistance of non‐small cell lung cancer cells. Our results demonstrated that CAF cells constitute a mechanism for cancer drug resistance. Thus, traditional chemotherapy combined with insulin‐like growth factor 2 (IGF2) signaling inhibitor may present an innovative therapeutic strategy for non‐small cell lung cancer therapy.

show abstract

Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma

Cited by 36 publications

References 14 publications

Fibroblast subtypes define a metastatic matrisome in breast cancer

Fibroblast subtypes define a metastatic matrisome in breast cancer

Activated Tumor-infiltrating Fibroblasts Predict Worse Prognosis in Breast Cancer Patients

Reverse of non‐small cell lung cancer drug resistance induced by cancer‐associated fibroblasts via a paracrine pathway

Contact Info

Product

Resources

About